Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2007 by Canadian Retinal Trials Group.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
University of British Columbia
QLT Inc.
Vancouver Hospital
Information provided by:
Canadian Retinal Trials Group
ClinicalTrials.gov Identifier:
NCT00148551
First received: September 6, 2005
Last updated: July 26, 2007
Last verified: July 2007
  Purpose

A 24 - month Study looking at the the changes in visual acuity of patients receiving PDT therapy in conjunction with intravitreal triamcinolone.


Condition Intervention Phase
Age-Related Macular Degeneration
Drug: Triamcinolone Acetonide
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Triamcinolone Acetonide as an Adjunctive Treatment to Verteporfin Therapy in Neovascular Age-Related Macular Degeneration: Randomized Placebo-Controlled Clinical Trial.

Resource links provided by NLM:


Further study details as provided by Canadian Retinal Trials Group:

Primary Outcome Measures:
  • Changes in visual acuity from baseline.

Secondary Outcome Measures:
  • Change in lesion characteristics from baseline.

Estimated Enrollment: 120
Study Start Date: January 2004
Estimated Study Completion Date: March 2008
Detailed Description:

This study will evaluate the effect of Triamcinolone Acetonide in conjunction with photodynamic therapy for the treatment of sub-foveal choroidal neovascular membranes secondary to age-related macular degeneration.

  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Individuals with predominantly classic, subfoveal CNV secondary to AMD.
  • No previous PDT Treatment in study eye.

Exclusion Criteria:

  • CNV from conditions, other than AMD.
  • Other disease that could be responsible for decreased vision.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00148551

Locations
Canada, British Columbia
Eye Care Centre
Vancouver, British Columbia, Canada
Sponsors and Collaborators
Canadian Retinal Trials Group
University of British Columbia
QLT Inc.
Vancouver Hospital
Investigators
Study Director: David A Maberley, M.D. University of British Columbia
  More Information

No publications provided by Canadian Retinal Trials Group

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00148551     History of Changes
Other Study ID Numbers: 01 (C03 - 0236)
Study First Received: September 6, 2005
Last Updated: July 26, 2007
Health Authority: Canada: Health Canada

Keywords provided by Canadian Retinal Trials Group:
AMD
Triamcinolone
Macular Degeneration

Additional relevant MeSH terms:
Macular Degeneration
Eye Diseases
Retinal Degeneration
Retinal Diseases
Triamcinolone
Triamcinolone Acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Anti-Inflammatory Agents
Enzyme Inhibitors
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 27, 2014